Lilly’s tirzepatide results in physique weight reductions in sort 2 diabetes trial


Eli Lilly and Company reported that the results of the SURPASS-2 clinical trial of tirzepatide showed superior reductions in A1C and body weight from baseline in adults with type 2 diabetes.

Tirzepatid is a novel once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist that combines the effects of both incretins in a single molecule.

The multicentre, randomized, parallel, open-label study analyzed the efficacy and safety of tirzepatide versus semaglutide in adults with type 2 diabetes who were inadequately controlled with ≥1500 mg / day metformin alone.

Semaglutide is a GLP-1 receptor agonist used to treat type 2 diabetes.

The study enrolled 1,879 subjects in the United States, United Kingdom, Argentina, Australia, Brazil, Canada, Israel and Mexico. They were randomized in a 1: 1: 1: 1 ratio to receive either a 5 mg, 10 mg, or 15 mg dose of tirzepatide or a 1 mg dose of semaglutide.

The data showed that tirzepatide produced superior reductions in A1C and body weight from baseline in participants versus semaglutide at all three doses tested.

The highest dose of tirzepatide reduced A1C by 2.46% and body weight by 12.4 kg, while the lowest dose A1C by 2.09% and body weight by 7.8 kg versus semaglutide at 1.86% and 6.2 kg reduced.

In addition, an A1C of less than 5.7% was achieved from 51% in the 15 mg tirzepatide arm versus 20% in the semaglutide arm.

The general safety profile of tirzepatide was similar to that previously reported, with the most commonly reported adverse events being gastrointestinal.

Thematic reports
Are you concerned about the pace of innovation in your industry?

In GlobalData’s TMT Themes 2021 report, you’ll find out everything you need to know about disruptive tech topics and which companies are best placed to digitally transform your business.

Find out more

Mike Mason, President of Lilly Diabetes, said, “Nearly nine out of ten people with type 2 diabetes in the US are overweight or suffer from obesity needs.

“These remarkable head-to-head results exceeded our expectations and supported our belief in the value of all three doses of tirzepatide as potential new treatment options for people with type 2 diabetes.”

Related companies


Organization of contract manufacturing and pharmaceutical supply services

August 28, 2020

OnAsset Intelligence

Global real-time tracking and monitoring solutions for clinical trials

August 28, 2020